BroadOak Capital Partners is proud to support Codis, building on the company’s scale, quality, and global reach.
The full press release is below.
ST. LOUIS, Oct. 16, 2025 /PRNewswire/ — Codis, a CDMO focused on commercial spray drying, amorphous solid dispersions (ASD), particle engineering, and finished-dose manufacturing, today announced a growth investment from 1315 Capital, with participation from existing shareholders BroadOak Capital Partners and Research Corporation Technologies (RCT). The funding will accelerate expansion of Codis’s commercial manufacturing capacity, with a focus on its Haverhill, UK facility.
Codis operates more than 400,000 square feet of cGMP facilities across St. Louis, MO; Seymour, IN; and Haverhill, UK, providing large-scale spray drying and related technologies for pharmaceutical, consumer health, nutraceutical, and OTC markets.
“We’re pleased to welcome 1315 Capital alongside RCT and BroadOak; this investment enables us to expand capacity in Haverhill to better support customers scaling to commercial supply,” said Nicolas Fortin, Chief Executive Officer of Codis.
“The pharmaceutical industry increasingly needs spray-drying expertise in order to produce amorphous solid dispersions, drug substances, and functional excipients,” said Matthew Reber, Partner at 1315 Capital. “We’re proud to partner with Codis as the company expands its commercial manufacturing offerings in these markets.”
“With capacity to produce more than 5,000 metric tons of spray-dried product annually, Codis operates one of the largest commercial spray-drying platforms worldwide,” said Shaun Kirkpatrick, President, Biotechnologies, RCT.
“This investment builds on Codis’s foundation of scale, quality, and global reach,” said Michael Caspani, Managing Director, BroadOak Capital Partners.
“Expanding Haverhill strengthens our global commercial network and shortens time to supply for customers,” said Derek Hennecke, Chairman of the Board.
